A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating “BRCAness” Genotype (ROAR)

Kamal Kant Sahu,Haoran Li,Vinay Mathew Thomas,Mallory Benson,Ken Boucher,Sumati Gupta,Manish Kohli,Umang Swami,Neeraj Agarwal,Benjamin L Maughan

DOI: https://doi.org/10.1093/oncolo/oyae030

2024-03-07

The Oncologist

Abstract:Abstract Background Both germline and somatic BReast CAncer gene (BRCA) mutations are poor prognostic markers in men with localized or metastatic prostate cancer. For instance, men with these mutations often are diagnosed with prostate cancer earlier and develop metastatic disease earlier compared with those who do not harbor similar mutations. Patients with germline alterations typically have more advanced disease and shorter overall survival (Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748-1757. doi:10.1200/JCO.2012.43.1882). The risk of disease progression to metastatic disease is significant in patients with this genotype of prostate cancer. The percentage of patients free from metastatic disease was 90%, 72%, and 50%, respectively, compared with 97%, 94%, and 84% at 3, 5, and 10 years for patients with intact DNA repair (P < .001) (Castro E, Goh C, Leongamornlert D, et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol. 2015;68(2):186-193. doi: 10.1016/j.eururo.2014.10.022). DNA damage repair non-BRCA mutations include alterations in genes such as ATM, CHEK2, PALB2, and RAD51. While less common than BRCA mutations, they have emerged as significant prognostic markers in prostate cancer. These BRCAness mutations are associated with a higher risk of aggressive disease and poorer survival outcomes. Given the debilitating physical and psychological side effects of androgen deprivation therapy (ADT) in relatively younger men with prostate cancer, delaying ADT in these men may be an attractive strategy. Given the proven efficacy of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors in the castration-resistant prostate cancersetting, PARP inhibitor monotherapy in a nonmetastatic castration-sensitive (nmCSPC) setting has the potential to delay metastasis and delay the onset of ADT related symptoms. Methods This is a single-arm, single-center, open-label, phase II trial to assess the efficacy of rucaparib in patients with high-risk biochemically recurrent (BCR) nmHSPC, which was defined as PSA doubling time of <9 months, demonstrating a “BRCAness” genotype (BRCA1/2 and other homologous recombination repair mutations). A total of 15 patients were intended to be enrolled, with an expected enrollment duration of 12 months. Patients were given rucaparib 600 mg orally twice daily and were allowed to remain on study treatment until PSA progression defined by Prostate Cancer Working Group 3, with 2 years of follow-up after study treatment. We anticipated a total of 2-3 years until completion of the clinical trial. The primary endpoint was to assess the PSA progression-free survival (PSA-PFS). The secondary endpoints of the study were safety, the proportion of patients with a PSA 50% response (PSA 50), and an undetectable PSA. A 4-week treatment duration comprised one cycle. Results The study started enrolling in June 2019 and was prematurely terminated in June 2022 after the accrual of 7 patients because of changing standard of care treatments with the introduction of next-generation scans, eg, prostate-specific membrane antigen positron emission tomography (PSMA-PET). Seven patients were enrolled in the study with the following pathogenic alterations: ATM (n = 3), BRCA2 (n = 2), BRCA1 (n = 1), BRIP1 (n = 1), and RAD51 (n = 1). The median duration of follow-up was 18 months. A median of 20 cycles (range 4-42) was completed, median PSA-PFS was 35.37 months (95% CI, 0-85.11 months). In total, 2 patients achieved PSA50; both also achieved nadir PSA as undetectable. Grade ≥ 3 adverse events (AEs) were anemia and rash (in 1 patient each). No dose-limiting toxicities or severe AEs were seen. Conclusion Rucaparib demonstrated acceptable toxicity and efficacy signal as an ADT-sparing approach in patients with biochemically recurrent nonmetastatic prostate cancer. It is currently challenging to understand the optimal value of systemic therapy in this disease setting due to the rapidly changing standard of care. Additionally, there are relatively few patients with BRCAness who present with nonmetastatic hormone-sensitive prostate cancer (ClinicalTrials.gov Identifier: NCT03533946).

oncology

What problem does this paper attempt to address?

### Problems the paper attempts to solve

This paper aims to explore the efficacy and safety of single - agent Rucaparib in non - metastatic, hormone - sensitive prostate cancer (nmCSPC) patients with the "BRCAness" genotype. Specifically, the study attempts to answer the following questions:

1. **Disease progression delay**: Can Rucaparib effectively delay PSA progression (PSA - PFS) and thus postpone the occurrence of metastasis?
2. **ADT side - effect reduction**: By using single - agent Rucaparib treatment, can the disease be controlled without androgen deprivation therapy (ADT), thus avoiding the side - effects brought by ADT?
3. **Quality of life improvement**: Compared with traditional ADT, do PARP inhibitors such as Rucaparib have less impact on the patient's quality of life?

### Background information

- **BRCA gene mutation**: Prostate cancer patients with BRCA gene mutations usually have a poorer prognosis, faster disease progression, and shorter survival time.
- **DNA repair defect**: In addition to the BRCA gene, mutations in other DNA repair genes (such as ATM, CHEK2, PALB2, etc.) are also associated with poor prognosis in prostate cancer.
- **Application of PARP inhibitors**: PARP inhibitors have been proven to have significant efficacy in metastatic castration - resistant prostate cancer (mCRPC), especially in patients with DNA repair defects.

### Research objectives

The main objective of this study is to evaluate the PSA progression - free survival (PSA - PFS) of single - agent Rucaparib in non - metastatic, hormone - sensitive prostate cancer patients with high - risk biochemical recurrence. Secondary objectives are to evaluate its safety, PSA50 response rate (a 50% decrease in PSA level), and the proportion of patients with undetectable PSA.

### Methods

This is a single - arm, single - center, open - label phase II clinical trial, with a planned recruitment of 15 patients. Patients take 600 mg of Rucaparib orally twice a day until PSA progression or unacceptable toxicity occurs. The primary endpoint is PSA - PFS, and secondary endpoints include safety and PSA response rate.

### Results

- **PSA - PFS**: The median PSA - PFS was 35.37 months (95% CI, 0 - 85.11 months).
- **PSA response**: Two patients achieved a PSA50 response and their PSA levels dropped to undetectable.
- **Safety**: All patients had adverse events, but no serious treatment - related adverse events (SAEs). The most common adverse events were fatigue and dysgeusia, and two patients had grade 3 adverse events (anemia and acne - like rash).

### Conclusions

Rucaparib shows acceptable toxicity and preliminary efficacy signals in non - metastatic, hormone - sensitive prostate cancer patients with the "BRCAness" genotype. This treatment strategy may help delay the use of ADT, thereby improving the patient's quality of life. However, due to changes in standard treatment (such as the introduction of PSMA - PET/CT imaging), the trial was terminated early.

### Significance

This study provides important clues for exploring the application of PARP inhibitors in the treatment of early - stage prostate cancer, especially in those patients with specific gene mutations. Future research needs to further verify these findings and explore the best treatment regimens to balance efficacy and quality of life.